If Shredders in ARC Raiders keep deleting you in seconds, here’s the fastest and safest way to beat them. These things look small, but the moment they spot you, they shoot forward and blast a full ...

Google’s own ‘code red’ response to ChatGPT has started paying off. Google’s own ‘code red’ response to ChatGPT has started paying off. is a London-based reporter at The Verge covering all things AI ...

Microsoft expanded its browser-based development tooling with recent updates to VS Code for the Web -- Azure, introducing faster entry points for moving AI-generated code into an editable, ...

The no-code movement is revolutionizing software development by allowing non-technical users to create applications without coding. Traditionally, software required extensive programming skills and ...

Anthropic introduces significant upgrades to Claude Code, enhancing autonomy with a native VS Code extension, terminal updates, and checkpoints for complex task management. Anthropic has unveiled a ...

The first preview release of the Swift SDK for Android was published this week, allowing developers to build Android apps in Swift with official tooling and making it easier to share code across iOS ...

Oct 14 (Reuters) - Salesforce (CRM.N), opens new tab expanded partnerships with OpenAI and Anthropic to integrate their frontier AI models into its Agentforce 360 platform, aiming to deliver ...

What if building your own AI agent was no longer a daunting task reserved for tech giants and elite developers? Imagine crafting a virtual assistant tailored to your business needs, a tutor designed ...

On Monday, Anthropic launched a new frontier model called Claude Sonnet 4.5, which it claims offers state-of-the-art performance on coding benchmarks. The company says Claude Sonnet 4.5 is capable of ...

Anthropic launched Claude Sonnet 4.5 on Monday, positioning the artificial intelligence model as "the best coding model in the world" in a direct challenge to OpenAI's recently released GPT-5, as the ...

Sept 24 (Reuters) - Acadia Pharmaceuticals (ACAD.O), opens new tab said on Wednesday it will discontinue development of its intranasal therapy to treat a rare genetic condition after it failed to show ...